NCT03691714View on ClinicalTrials.gov

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Recurrent Head and Neck CancerHead and Neck CancerHead and Neck NeoplasmsMetastatic Cancer
Interventions
DRUG

Durvalumab

Two hour infusion

DRUG

Cetuximab

Two hour infusion for loading dose followed by weekly one hour infusion

Trial Locations (1)

45219

UC Health, Cincinnati

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Trisha Wise-Draper

OTHER

NCT03691714 - Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter